These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 26728463)

  • 1. Mutations in Complement Factor H Impair Alternative Pathway Regulation on Mouse Glomerular Endothelial Cells in Vitro.
    Loeven MA; Rops AL; Lehtinen MJ; van Kuppevelt TH; Daha MR; Smith RJ; Bakker M; Berden JH; Rabelink TJ; Jokiranta TS; van der Vlag J
    J Biol Chem; 2016 Mar; 291(10):4974-81. PubMed ID: 26728463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective Binding of Heparin/Heparan Sulfate Oligosaccharides to Factor H and Factor H-Related Proteins: Therapeutic Potential for C3 Glomerulopathies.
    Loeven MA; Maciej-Hulme ML; Yanginlar C; Hubers MC; Kellenbach E; de Graaf M; van Kuppevelt TH; Wetzels J; Rabelink TJ; Smith RJH; van der Vlag J
    Front Immunol; 2021; 12():676662. PubMed ID: 34489931
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutations of factor H impair regulation of surface-bound C3b by three mechanisms in atypical hemolytic uremic syndrome.
    Lehtinen MJ; Rops AL; Isenman DE; van der Vlag J; Jokiranta TS
    J Biol Chem; 2009 Jun; 284(23):15650-8. PubMed ID: 19351878
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disturbed sialic acid recognition on endothelial cells and platelets in complement attack causes atypical hemolytic uremic syndrome.
    Hyvärinen S; Meri S; Jokiranta TS
    Blood; 2016 Jun; 127(22):2701-10. PubMed ID: 27006390
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural and functional characterization of the product of disease-related factor H gene conversion.
    Herbert AP; Kavanagh D; Johansson C; Morgan HP; Blaum BS; Hannan JP; Barlow PN; Uhrín D
    Biochemistry; 2012 Mar; 51(9):1874-84. PubMed ID: 22320225
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recognition of malondialdehyde-modified proteins by the C terminus of complement factor H is mediated via the polyanion binding site and impaired by mutations found in atypical hemolytic uremic syndrome.
    Hyvärinen S; Uchida K; Varjosalo M; Jokela R; Jokiranta TS
    J Biol Chem; 2014 Feb; 289(7):4295-306. PubMed ID: 24344133
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Binding of complement factor H to endothelial cells is mediated by the carboxy-terminal glycosaminoglycan binding site.
    Jokiranta TS; Cheng ZZ; Seeberger H; Jòzsi M; Heinen S; Noris M; Remuzzi G; Ormsby R; Gordon DL; Meri S; Hellwage J; Zipfel PF
    Am J Pathol; 2005 Oct; 167(4):1173-81. PubMed ID: 16192651
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual interaction of factor H with C3d and glycosaminoglycans in host-nonhost discrimination by complement.
    Kajander T; Lehtinen MJ; Hyvärinen S; Bhattacharjee A; Leung E; Isenman DE; Meri S; Goldman A; Jokiranta TS
    Proc Natl Acad Sci U S A; 2011 Feb; 108(7):2897-902. PubMed ID: 21285368
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of heparan sulfate as determining pathogenic factor in complement factor H-associated diseases.
    Loeven MA; Rops AL; Berden JH; Daha MR; Rabelink TJ; van der Vlag J
    Mol Immunol; 2015 Feb; 63(2):203-8. PubMed ID: 25246018
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Microbes bind complement inhibitor factor H via a common site.
    Meri T; Amdahl H; Lehtinen MJ; Hyvärinen S; McDowell JV; Bhattacharjee A; Meri S; Marconi R; Goldman A; Jokiranta TS
    PLoS Pathog; 2013; 9(4):e1003308. PubMed ID: 23637600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure of complement factor H carboxyl-terminus reveals molecular basis of atypical haemolytic uremic syndrome.
    Jokiranta TS; Jaakola VP; Lehtinen MJ; Pärepalo M; Meri S; Goldman A
    EMBO J; 2006 Apr; 25(8):1784-94. PubMed ID: 16601698
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Both domain 19 and domain 20 of factor H are involved in binding to complement C3b and C3d.
    Bhattacharjee A; Lehtinen MJ; Kajander T; Goldman A; Jokiranta TS
    Mol Immunol; 2010 May; 47(9):1686-91. PubMed ID: 20378178
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An engineered construct combining complement regulatory and surface-recognition domains represents a minimal-size functional factor H.
    Hebecker M; Alba-Domínguez M; Roumenina LT; Reuter S; Hyvärinen S; Dragon-Durey MA; Jokiranta TS; Sánchez-Corral P; Józsi M
    J Immunol; 2013 Jul; 191(2):912-21. PubMed ID: 23772024
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unraveling the Effect of a Potentiating Anti-Factor H Antibody on Atypical Hemolytic Uremic Syndrome-Associated Factor H Variants.
    Dekkers G; Brouwer MC; Jeremiasse J; Kamp A; Biggs RM; van Mierlo G; Lauder S; Katti S; Kuijpers TW; Rispens T; Jongerius I
    J Immunol; 2020 Oct; 205(7):1778-1786. PubMed ID: 32848031
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of surface recognition and C3b binding properties of mouse and human complement factor H.
    Cheng ZZ; Hellwage J; Seeberger H; Zipfel PF; Meri S; Jokiranta TS
    Mol Immunol; 2006 Mar; 43(7):972-9. PubMed ID: 16023208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Crystallographic determination of the disease-associated T1184R variant of complement regulator factor H.
    Morgan HP; Jiang J; Herbert AP; Kavanagh D; Uhrin D; Barlow PN; Hannan JP
    Acta Crystallogr D Biol Crystallogr; 2011 Jul; 67(Pt 7):593-600. PubMed ID: 21697597
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The endothelial glycocalyx as a potential modifier of the hemolytic uremic syndrome.
    Boels MG; Lee DH; van den Berg BM; Dane MJ; van der Vlag J; Rabelink TJ
    Eur J Intern Med; 2013 Sep; 24(6):503-9. PubMed ID: 23357408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tissue-specific host recognition by complement factor H is mediated by differential activities of its glycosaminoglycan-binding regions.
    Clark SJ; Ridge LA; Herbert AP; Hakobyan S; Mulloy B; Lennon R; Würzner R; Morgan BP; Uhrín D; Bishop PN; Day AJ
    J Immunol; 2013 Mar; 190(5):2049-57. PubMed ID: 23365078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disease-associated N-terminal complement factor H mutations perturb cofactor and decay-accelerating activities.
    Pechtl IC; Kavanagh D; McIntosh N; Harris CL; Barlow PN
    J Biol Chem; 2011 Apr; 286(13):11082-90. PubMed ID: 21270465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deregulation of Factor H by Factor H-Related Protein 1 Depends on Sialylation of Host Surfaces.
    Dopler A; Stibitzky S; Hevey R; Mannes M; Guariento M; Höchsmann B; Schrezenmeier H; Ricklin D; Schmidt CQ
    Front Immunol; 2021; 12():615748. PubMed ID: 33732239
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.